牛牛AI助理已提取核心訊息
Brett A. Giffin, the Chief Commercial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 13 shares of common stock. The transaction was classified as an exercise or conversion of derivative security, as per the transaction code 'M'. Following this transaction, Giffin's direct holdings in the company increased to a total of 77 shares of common stock. The transaction reflects a continued investment by the executive in the company, signaling confidence in T2 Biosystems' prospects.
Brett A. Giffin, the Chief Commercial Officer of T2 Biosystems, Inc. (TTOO), executed a transaction on February 20, 2024, involving the acquisition of 13 shares of common stock. The transaction was classified as an exercise or conversion of derivative security, as per the transaction code 'M'. Following this transaction, Giffin's direct holdings in the company increased to a total of 77 shares of common stock. The transaction reflects a continued investment by the executive in the company, signaling confidence in T2 Biosystems' prospects.
T2 Biosystems, Inc.（TTOO）的首席商務官佈雷特·吉芬於2024年2月20日執行了一項交易，涉及收購13股普通股。根據交易代碼 “M”，該交易被歸類爲衍生證券的行使或轉換。在這筆交易之後，Giffin在該公司的直接持有量增加到總共77股普通股。該交易反映了該高管對該公司的持續投資，表明了對T2 Biosystems前景的信心。
T2 Biosystems, Inc.（TTOO）的首席商務官佈雷特·吉芬於2024年2月20日執行了一項交易，涉及收購13股普通股。根據交易代碼 “M”，該交易被歸類爲衍生證券的行使或轉換。在這筆交易之後，Giffin在該公司的直接持有量增加到總共77股普通股。該交易反映了該高管對該公司的持續投資，表明了對T2 Biosystems前景的信心。
有用
沒用